The therapy of a patient suffering from secondary narcolepsy is described. The illness and the function of the symptom as a defense-mechanism are analysed. Sleep appears to be an ontogenetically archaic reaction to extreme--real and neurotic--dangers, which there is not possibility to escape from. The defense against extreme dangers is the withdrawal of all object-cathexis; following Freuds explanations this means: Sleep. In the patient the danger consisted of a regression to a narcisstic position: The symptom helped to avoid a separation of instincts in form of on the one hand narcisstic rage, on the other hand symbiosis. Taking into account the ideas of Spitz, the concept of fusion and separation of instincts is discussed.20
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy of sodium oxybate versus placebo on improvement of nighttime sleep in adult patients with narcolepsy: A systematic review and meta-analysis.
Sleep Med X
December 2025
Hamad Medical Corporation, Doha, Qatar.
Background: Narcolepsy, a central hypersomnolence disorder, disrupts sleep regulation. Sodium oxybate, a CNS (central nervous system) depressant, is widely used as a treatment, but there are surprisingly very few rigorous studies comparing its effectiveness to placebo in adults.
Objectives: To measure the comparative efficacy of sodium oxybate at a dosage regimen of 9 g versus placebo in improving nighttime sleep quality, reducing nocturnal arousals and sleep stage shifts, and enhancing the overall refreshed nature of sleep in adult patients with narcolepsy.
Z hypnotics in the management of narcolepsy: a case series.
J Clin Sleep Med
December 2024
Sleep Disorders & Research Center, Department of Sleep Medicine, Henry Ford Health System, Detroit, MI.
Study Objectives: Here we report our experience treating patients with narcolepsy using benzodiazepine receptor agonists (BzRA), zolpidem (Zol) or eszopiclone (Esz) taken at bedtime for both excessive daytime sleepiness (EDS) and cataplexy.
Methods: We reviewed the medical records of 53 patients diagnosed with narcolepsy, between 2002 and 2023. Twenty-three patients, 8 with type1 (NT1), 13 with type 2 (NT2) and 2 with secondary narcolepsy, were treated with BzRA's (20 Zol and 3 Esz).
Epidemiology, patient characteristics, and treatment patterns of patients with narcolepsy in Sweden: a non-interventional study using secondary data.
Sleep Adv
December 2024
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Study Objectives: To estimate the prevalence and incidence and evaluate the treatment patterns of patients diagnosed with narcolepsy in specialist care in Sweden.
Methods: This non-interventional retrospective longitudinal study used Swedish register data from 2010 to 2020 and included patients diagnosed with narcolepsy (either type 1 or type 2), recorded in specialist outpatient and inpatient care from January 2015 to December 2019. All patients received an index date corresponding to the date of the first narcolepsy diagnosis.
Trends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022.
J Sleep Res
December 2024
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Clinicians and people with narcolepsy report varied access to higher-cost narcolepsy treatments in England associated with variations in national and local commissioning. There are no publicly available data quantifying use of these drugs to support policy decisions. We therefore aimed to describe national, regional and local prescribing trends for higher-cost narcolepsy drugs using new national databases.
View Article and Find Full Text PDFEfficacy and safety of sodium oxybate treatment in adults with narcolepsy and cataplexy: a systematic review and meta-analysis.
Sleep Breath
November 2024
Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Article Synopsis
- Narcolepsy is a chronic condition marked by excessive daytime sleepiness and cataplexy, and sodium oxybate (SXB) has been identified as the only effective treatment for its symptoms.
- The study reviewed five randomized controlled trials (RCTs) to evaluate the effectiveness of SXB in reducing cataplexy attacks and improving wakefulness while also considering its safety by monitoring adverse events.
- Results showed that SXB significantly reduced weekly cataplexy attacks and improved outcomes on various tests compared to placebo, particularly at higher doses, indicating it is an effective treatment for managing narcolepsy symptoms with a reasonably safe profile.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!